If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Professor William Sievert is a clinician-scientist with dual appointments at Monash University and Monash Health as the Director of the Gastrointestinal and Liver Unit. Professor Sievert has a long-term interest in liver disease and directs an active clinical research unit comprising physician-scientists, clinical research nurses and research students.

The Clinical Research Unit has been continuously active over ten years and regularly contributes to international trials of new antiviral agents for hepatitis B and C in addition to developing and leading national investigator-initiated studies. He also directs a basic research laboratory investigating mechanisms of inflammatory liver injury and hepatic fibrogenesis, with a translational focus on identification and development of potential hepatic antifibrotic agents.

Professor Sievert is also active in medical education including the development of new undergraduate and graduate medical curricula at Monash University.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial

Yuen, M. F., Agarwal, K., Gane, E. J., Schwabe, C., Ahn, S. H., Kim, D. J., Lim, Y. S., Cheng, W., Sievert, W., Visvanathan, K., Ruby, E., Liaw, S., Yan, R., Huang, Q., Colonno, R. & Lopatin, U., 1 Feb 2020, In : The Lancet Gastroenterology & Hepatology. 5, 2, p. 152-166 15 p.

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels

Nicoll, A. J., Roberts, S. K., Lim, R., Mitchell, J., Weltman, M., George, J., Wigg, A., Stuart, K., Gow, P., MacQuillan, G., Tse, E., Levy, M., Sood, S., Zekry, A., Cheng, W., Mitchell, J., Skoien, R., Sievert, W., Strasser, S. I., McCaughan, G. W. & 1 others, on behalf of the ALA Clinical Research Network, Gastroenterological Society of Australia, 1 May 2019, In : Alimentary Pharmacology & Therapeutics. 49, 10, p. 1314-1322 9 p.

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Human amnion epithelial cells and their soluble factors reduce liver fibrosis in murine non-alcoholic steatohepatitis

Kuk, N., Hodge, A., Sun, Y., Correia, J., Alhomrani, M., Samuel, C., Moore, G., Lim, R. & Sievert, W., Aug 2019, In : Journal of Gastroenterology and Hepatology. 34, 8, p. 1441-1449 9 p.

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Impact of preexisting hepatitis C virus genotype 6 NS3, NS5A, and NS5B polymorphisms on the in vitro potency of direct-acting antiviral agents

McPhee, F., Ueland, J., Vellucci, V., Bowden, S., Sievert, W. & Zhou, N., 1 Apr 2019, In : Antimicrobial Agents and Chemotherapy. 63, 4, 12 p., e02205-18.

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse

Papaluca, T., Sinclair, M., Gow, P., Pianko, S., Sievert, W., Arachchi, N., Cameron, K., Bowden, S., O’Keefe, J., Doyle, J., Stoove, M., Hellard, M., Iser, D. & Thompson, A., 1 Dec 2019, In : Liver International. 39, 12, p. 2285-2290 6 p.

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)